Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

Fig. 3

DEC decelerates ALL engraftment in vivo. a Demonstration of in vivo monitoring of luciferase expression after injection of luciferase and monitored by BLI (ph/s) in SEM-ffluc xenograft mice. Demonstrated are mice after treatment with saline-, DEC- and DEC + AraC-treated mice during 30 days (four representative mice per group). DEC-treated mice show decelerated leukemia cell proliferation as indicated with a lower BLI signal compared to saline-treated mice. b Quantification of BLI signals (ph/s) was performed by adding whole body luminescence signals of prone and supine acquisition. BLI signals are summarized as mean ± SD for SEM-ffluc (saline: n = 9, DEC: n = 9, DEC + AraC: n = 9)- and RS4;11-ffluc (saline: n = 9, DEC: n = 9)-derived xenografts. Significant treatment effects are labeled with * (p < 0.05)

Back to article page